SHARE NOW
Bio-Techne Corporation, Bio-Techne, has confirmed that it will showcase its product portfolio and solutions to enable cell and gene therapy development and manufacturing at Advanced Therapies Week 2024, featuring its wide range of products, services and capabilities to demonstrate the enablement of cell and gene therapy development and workflow solutions.
Bio-Techne has confirmed attendance at Advanced Therapies Week 2024, January 16-19, and will be at booth #509, featuring its wide range of products, services and capabilities to demonstrate the enablement of cell and gene therapy development and workflow solutions.
Particularly, on Friday, January 19 at 10:00 AM EST David Hermanson, Director for Cell & Gene Therapy Applications at Bio-Techne, will present a technical talk on the non-viral gene editing TcBuster™ transposon system. The technical talk will focus on how gene-modified cell therapies can be manufactured at scale using the TcBuster transposon system, specialty media, and liquid cytokines in the G-Rex® bioreactor.
“My presentation will be a wonderful opportunity for attendees to learn how immune cell therapy development programs can benefit from a streamlined T cell manufacturing workflow and licensable transposon system for non-viral gene engineering,” highlighted Dr. Hermanson.
Dr. Hermanson’s talk will also describe how automated Simple Plex™ immunoassays on Ella™ can be used for the functional assessment of CART cells.
How are you enjoying this news article? Let us know your thoughts, here >>
There will also be hosting a roundtable discussion bringing together industry leaders to discuss the importance of scalable and cost-effective closed-system solutions for CAR-T cell manufacturing featuring ScaleReady, Bio-Techne’s strategic partnership with Fresenius Kabi and Wilson Wolf for integrated immune cell therapy manufacturing workflow solutions.
“In partnership with ScaleReady, Bio-Techne is proud to offer flexible cell and gene therapy workflow solutions that simplify the transition from RUO to GMP and allow for seamless process scale-up, enabling our customers to get their therapies to the clinic with speed and consistency,” said Will Geist, President of Bio-Techne’s Protein Sciences Segment.
Technical Talk with David Hermanson, PhD as Presenter, Friday, January 19th at 10:00 AM EST, Theatre 2
- Non-Viral Manufacturing of Gene Modified CAR T Therapies Using TcBuster™
- Presentation: Non-Viral Solutions for Gene Therapy
Roundtable Talk, Thursday, January 18th, at 8:00 AM EST, Theatre 2
Cell Therapy Manufacturing: A Look Under the Hood – Learning from Outside the Industry. Can we make CAR-T cells like we make cars?
- Josh Ludwig, Global Commercial Director ScaleReady – Moderator
- Ignacio Nunez, Founder and CEO BioExcellence LLC – Presenter and panelist
- Ricardo Jimenez, SVP Tech Ops at Neurogene – Panelist Sarah Madonna, Sr Dir Manufacturing at Kiromic Biopharma – Panelist
- Nick Casale, VP Global Facilities & Corporate Engineering Ultragenyx Pharmaceutical– Panelist About Bio-Techne
Visit Bio-Techne at booth #509
Source: Bio-Techne Corporation Press Release
Yet to confirm your place? Book your ticket now >>
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
